Ajanta Pharma Announces Approval & Launch of Amlodipine + Olmesartan Medoxomil Tablets in US Market

Press Release (ePRNews.com) - MUMBAI, India - Nov 02, 2016 - Ajanta Pharma Announces Approval & Launch of

Amlodipine + Olmesartan Medoxomil Tablets in US Market

Mumbai, India – Ajanta Pharma Limited, announces today US FDA* approval and launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.  It is a bioequivalent generic version of Azor®1 tablets and company has launched the product in 4 strengths, 5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg tablets.

Amlodipine + OlmesartanMedoxomil Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Application (ANDA) of which it has for 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with US FDA.

About Ajanta Pharma

Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

For the financial year ended 31st March, 2016, Ajanta’s consolidated revenue stood at Rs. 1,728 cr. (USD 261 million) and net profit stood at Rs. 401 cr. (USD 61 million).  For the last 5 years, Ajanta Pharma has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.

For more information on Ajanta Pharma Ltd., please visit www.ajantapharma.com and for Ajanta Pharma USA Inc., please visit www.ajantapharmausa.com

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email:rajeev.agarwal@ajantapharma.com

* United States Food & Drug Administration

1Azor® is a registered trademark of Daiichi Sankyo Inc.

Safe Harbour Statement (http://www.ajantapharma.com/Safe-Harbour.html)

Source : Ajanta Pharma Limited
Business Info :
Ajanta Pharma Limited

You may also like this  

CATEGORIES : Healthcare
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login